US FDA finds new manufacturing lapses at Eli Lilly plant

,
Eli Lilly

US FDA finds new manufacturing lapses at Eli Lilly plant

WASHINGTON, Jan 19 (Reuters) – U.S. inspectors recently uncovered new manufacturing problems at an Eli Lilly (LLY.N) plant that has been under scrutiny by federal investigators, according to government records obtained by Reuters.
 
The U.S. Food and Drug Administration inspection in July at Lilly’s Branchburg, New Jersey, plant detected eight separate deficiencies. They included problems in tracking manufacturing process and quality controls, as well as lapses in its calibration of equipment and failure to properly maintain facilities and equipment, the inspection report shows.